Non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Chiba University Hospital
Funabashi Municipal Medical Center, Chiba Cancer Center Research Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible cases are those who meet either (1) or (2) below and also meet (3). (1) Patients with advanced or recurrent non-small cell lung cancer with a performance status (PS) of 0-1 who have started initial systemic chemotherapy with a regimen containing carboplatin. (2) Patients with advanced or recurrent non-small cell lung cancer with a PS of 0-1 who have started initial systemic chemotherapy with a regimen containing carboplatin after molecular targeted drug therapy. (3) Patients who started initial treatment between January 1, 2019 and December 31, 2022.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will be excluded. Those who have expressed refusal to participate in this study through a disclosure document. Cases in which initial systemic chemotherapy was administered after unplanned emergency hospitalization. Those treated with the Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel (ABCP) regimen (In reality, it takes more than 5-6 hours to administer the drugs, making it difficult to administer the regimen in an outpatient chemotherapy room. Therefore, it is not possible to compare the outpatient and inpatient groups.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Completion rate of 4 chemotherapy courses | — |
Secondary
| Measure | Time frame |
|---|---|
| Unscheduled medical visit rate up to 4 cycles, Adverse events of grade 3 or higher, Progression-free survival, Overall survival, Dose reduction rate during 4 cycles of treatment | — |
Countries
Japan
Contacts
Public ContactFujihiro Kure
Chiba University Hospital Department of Respiratory medicine
Outcome results
None listed